REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will provide a corporate overview and business update at the Oppenheimer 26th Annual Healthcare Conference.
| Presentation Details: | |
| Title: | Oppenheimer 26th Annual Healthcare Conference |
| Date: | Tuesday, December 8 |
| Time: | 10:55am Eastern Time |
| Location: | Westin New York Grand Central, New York City |
| Webcast: | https://www.veracast.com/webcasts/opco/healthcare2015/79106250515.cfm |
About Foamix Pharmaceuticals Ltd.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals’ lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: Ilan Hadar, CFO
Foamix Pharmaceuticals Ltd.
+972-8-9316233
ilan.hadar@foamixpharma.com
U.S. Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6979
mrice@lifesciadvisors.com
